(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 10.3% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Exagen's revenue in 2026 is $66,575,000.On average, 8 Wall Street analysts forecast XGN's revenue for 2026 to be $1,731,339,115, with the lowest XGN revenue forecast at $1,661,128,239, and the highest XGN revenue forecast at $1,805,783,329. On average, 9 Wall Street analysts forecast XGN's revenue for 2027 to be $1,953,420,999, with the lowest XGN revenue forecast at $1,849,704,213, and the highest XGN revenue forecast at $2,136,633,142.
In 2028, XGN is forecast to generate $2,132,977,077 in revenue, with the lowest revenue forecast at $2,069,621,323 and the highest revenue forecast at $2,217,451,417.